Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

The results were stunning. So too was the nationality of the company behind them. Akeso, a biotech firm, is Chinese.

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Hanmi Pharmaceutical confirms positive results for Tibumeshirnon and Keytruda in cancer trial Phase 2 trial highlights ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...